Sunrock Biopharma SL and Shanghai Escugen Biotechnology Co. Ltd. have joined forces in a strategic partnership to codevelop SRB-123, a first-in-class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer.

CSPC Pharmaceutical Group Ltd. has entered into a strategic research collaboration agreement with Astrazeneca plc for the discovery and development of novel oral small-molecule candidates utilizing the group’s AI-driven, dual-engine efficient drug discovery platform.

Archeus Technologies Inc. and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule, into clinical development for prostate cancer.

Quralis Corp. has entered into a number of agreements with the aim of advancing the treatment of fragile X syndrome, a genetic condition caused by a mutation of a single gene – fragile X messenger ribonucleoprotein 1 (FMR1) – on the X chromosome.

Genprex Inc. and University of Pittsburgh have entered into a new sponsored research agreement (SRA) to study GPX-002, Genprex’s gene therapy for diabetes in animal models of type 1 and type 2 diabetes.

Viverita Therapeutics Inc. has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG aimed at accelerating the discovery and validation of novel therapeutic targets for cancer.

Odylia Therapeutics Inc. has announced it is working under a codevelopment partnership with the NPHP1 Family Foundation to create an AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene.

Abtherx Inc. has signed a technology license agreement with Rondo Therapeutics with the aim of accelerating Rondo’s pipeline of bispecific antibodies. Rondo aims to advance the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies.